Lantern Pharma Advances AI-Driven Cancer Therapies

Lantern Pharma, Inc. ( (LTRN) ) has released its Q1 earnings. Here is a breakdown of the information Lantern Pharma, Inc. presented to its investors.

Lantern Pharma, Inc. is a clinical-stage biopharmaceutical company that utilizes its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to innovate and accelerate oncology drug discovery and development. The company is known for its focus on precision oncology and its AI-driven approach to developing drug candidates for various cancer indications.

In its first quarter 2025 earnings report, Lantern Pharma highlighted significant advancements in its clinical trials and AI technology. The company completed enrollment for the LP-184 Phase 1a clinical trial and anticipates additional data readouts from its HARMONIC™ Trial for LP-300 in non-small cell lung cancer (NSCLC) by Q3 2025. Lantern Pharma also expanded its AI intellectual property portfolio and announced plans to launch select RADR® AI modules for the scientific community.

Key financial metrics for the quarter included a reduction in net loss to $4.5 million from $5.4 million in the previous year, with research and development expenses decreasing to $3.3 million. The company maintained a strong cash position with $19.7 million in cash, cash equivalents, and marketable securities, providing an operating runway through mid-2026. Additionally, Lantern Pharma’s RADR® platform reached a milestone with 200 billion oncology-focused data points, enhancing its drug development capabilities.

Strategic announcements included plans for future clinical trials, such as a Phase 1b/2 study in triple-negative breast cancer (TNBC) and a trial targeting drug-resistant NSCLC with specific genetic mutations. Lantern Pharma is also preparing for an exploratory trial in recurrent bladder cancer and advancing its subsidiary, Starlight Therapeutics, for CNS and brain cancer therapies.

Looking ahead, Lantern Pharma is poised to continue leveraging its AI platform to drive oncology drug development and explore collaborative opportunities with biopharma partners. The company’s focus remains on addressing unmet patient needs and advancing its pipeline toward commercialization, with an estimated market potential exceeding $15 billion annually.